This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Verapamil and hyperprolactinaemia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • verapamil has a significant prolactin releasing effect - a study revealed that 8.5% of male patients treated with verapamil had increased prolactin levels with a concomitant reduction in testosterone levels (1) - this prolactin releasing effect is not significant with other calcium antagonists

  • verapamil may lead to hyperprolactinaemia via antagonism of N-type calcium channels and consequent decrease in central dopamine production

Reference:

  • 1) Romeo JH et al. Hyperprolactinaemia and verapamil: prevalence and potential association with hypogonadism in men. Clin Endocrinol (Oxf) 1996;45:571-5.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.